BioCorRx Reports Q1 2026 Results: Revenue Up 59%, Cash Burn Improves Amidst Ongoing Going Concern

summarizeSummary

BioCorRx reported Q1 2026 results with 59% revenue growth and improved cash burn, but remains a going concern with persistent material weaknesses and high customer concentration. The President made a significant $500,000 stock purchase.

check_boxKey Events

• Going Concern Warning Continues

  The company maintains a going concern warning with a working capital deficit of $7.5 million as of March 31, 2026, indicating ongoing financial challenges.

• Strong Revenue Growth and Improved Cash Burn

  Q1 2026 revenue increased by 59% to $214,539, driven by Lucemyra sales. Net cash used in operating activities improved to $432,971, a reduction from $689,623 in the prior year.

• Significant Dilutive Financing and Insider Investment

  The company issued 4.4 million shares in Q1 2026, increasing shares outstanding by 18% since year-end 2025. This includes a $500,000 stock purchase by President Louis C Lucido at $0.34 per share, demonstrating insider confidence despite dilution.

• Persistent Material Weaknesses and High Customer Concentration

  Material weaknesses in internal controls over financial reporting were again noted. The company also faces significant concentration risk, with 99% of Q1 revenue and 100% of accounts receivable from two customers.

auto_awesomeAnalysis

BioCorRx Inc. filed its Q1 2026 earnings report, continuing to operate under a going concern warning due to recurring losses and a working capital deficit of $7.5 million. Despite these challenges, the company reported a significant 59% increase in revenue to $214,539, primarily driven by Lucemyra distribution sales. Net cash used in operating activities improved to $432,971, down from $689,623 in the prior year, indicating a reduced cash burn. However, the company continues to rely on dilutive financing, with 4.4 million shares issued in Q1 2026, including a $500,000 stock purchase by President Louis C Lucido at $0.34 per share. Material weaknesses in internal controls persist, and the company faces high customer concentration, with 99% of Q1 revenue and 100% of accounts receivable from just two customers. Subsequent to quarter-end, additional shares were issued for compensation and a promissory note amendment.